At a glance
ClinicalIndex Comparison RecordN/ACompleted· 13 enrolled
Drug / intervention
Carbon dioxide, USP +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intranasal CO2 for Allergic Rhinitis
In Brief
A clinical study evaluating Carbon dioxide, USP and Placebo for Allergic Rhinitis. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The purpose of this study is to better understand the way in which CO2 (carbon dioxide) affects the symptoms of allergic rhinitis or hayfever. Our intent is to determine if CO2 has an effect on nasal challenge with antigen as a predictor of whether it will have a beneficial effect on the treatment of seasonal allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesUnited States
CollaboratorsCapnia, Inc.
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedFeb 2008
Primary CompletionApr 2008
Study CompletionSep 2008
TodayJul 2026
First PostedFeb 20, 2008
Enrollment StartFeb 1, 2008
Primary CompletionApr 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.4 years ago
Interventions
Carbon dioxide, USPdevice
Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
Placeboother
Nasal placebo